1. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
- Author
-
Zhu G, Yang Y, Wang H, Xie J, Hu J, Guo W, Zhang L, Liu Z, Chen X, Chang J, Xu J, and Tan Y
- Subjects
- Adult, Aged, Biomarkers, Pharmacological analysis, Biomarkers, Pharmacological blood, China, Disease-Free Survival, Female, Fusion Proteins, bcr-abl analysis, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Male, Middle Aged, Molecular Targeted Therapy methods, Protein Kinase Inhibitors pharmacology, Protein-Tyrosine Kinases antagonists & inhibitors, Protein-Tyrosine Kinases metabolism, Recurrence, Remission Induction methods, Fusion Proteins, bcr-abl genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Polymerase Chain Reaction methods
- Abstract
Treatment-free remission (TFR) is emerging as a new therapy goal for chronic myeloid leukemia (CML) patients in the tyrosine kinase inhibitors (TKI) era. Data indicates the unfavorable success rate of TFR. This study aimed to compare and evaluate the clinical value of dd-PCR in predicting relapse in CML patients entering TFR. Using dd-PCR and RT-qPCR technology, dynamic BCR/ABL transcripts were detected in 13 CML patients who discontinued TKI treatment after sustaining undetectable BCR-ABL levels for a median time of 25 months. The results showed that in 13 patients, only 2 cases (22.2%) of 9 patients who executed planned discontinuation achieved TFR within 12 months. In the first 6 months, the detection rate of BCR/ABL transcripts by dd-PCR was higher than that by RT-qPCR and the two methods kept a positive correlation (r=0.9651, P =0.0349). Meanwhile, the time of detectable BCR/ABL by dd-PCR were significantly shorter ( P <0.05), which was an average of 2.98 months earlier than RT-qPCR. The total TKI therapy and MR4.5 duration time related with TFR were longer in patients with intermediate or high Sokal risk scores ( p <0.05). The dd-PCR could be more sensitive than RT-qPCR for monitoring BCR/ABL transcripts of CML patients with deep molecular response to TKI. The technique can be used as a preferred method to detect the transcripts in the first 6 months after TKI cessation., (© 2020 by the Association of Clinical Scientists, Inc.)
- Published
- 2020